Karuna Therapeutics Neutral Rating Reiterated at JPMorgan Chase Co.
KRTXDelisted Stock | USD 203.11 1.46 0.71% |
Slightly above 62% of Karuna Therapeutics' investor base is looking to short. The analysis of current outlook of investing in Karuna Therapeutics suggests that many traders are alarmed regarding Karuna Therapeutics' prospects. Karuna Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Karuna Therapeutics' earnings reports, geopolitical events, and overall market trends.
Karuna |
JPMorgan Chase Co. restated their neutral rating on shares of Karuna Therapeutics in a report published on Thursday morning, Benzinga reports. They currently have a 330.00 target price on the stock, up from their previous target price of 217.00. KRTX has been the subject of several other reports. JMP Securities
Read at thelincolnianonline.com
Karuna Therapeutics Fundamental Analysis
We analyze Karuna Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Karuna Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Karuna Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Number Of Employees
Number Of Employees Comparative Analysis
Karuna Therapeutics is currently under evaluation in number of employees category among its peers. Number of Employees shows the total number of permanent full time and part time employees working for a given company and processed through its payroll.
Karuna Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Karuna Therapeutics stock to make a market-neutral strategy. Peer analysis of Karuna Therapeutics could also be used in its relative valuation, which is a method of valuing Karuna Therapeutics by comparing valuation metrics with similar companies.
Peers
Karuna Therapeutics Related Equities
INZY | Inozyme Pharma | 9.56 | ||||
TERN | Terns Pharmaceuticals | 5.17 | ||||
MREO | Mereo BioPharma | 1.58 | ||||
BPMC | Blueprint Medicines | 0.87 | ||||
XFOR | X4 Pharmaceuticals | 0.45 | ||||
CYTK | Cytokinetics | 0.1 | ||||
APLS | Apellis Pharmaceuticals | 1.09 | ||||
DYN | Dyne Therapeutics | 1.19 | ||||
DAWN | Day One | 1.86 | ||||
EWTX | Edgewise Therapeutics | 2.58 | ||||
ABOS | Acumen Pharmaceuticals | 3.56 | ||||
AMLX | Amylyx Pharmaceuticals | 7.58 |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Other Consideration for investing in Karuna Stock
If you are still planning to invest in Karuna Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Karuna Therapeutics' history and understand the potential risks before investing.
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Transaction History View history of all your transactions and understand their impact on performance | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets |